Cooper Cos. (COO) Acquires AEGEA Medical
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CooperSurgical announced today the acquisition of California-based, AEGEA Medical and its FDA-approved Mara™ Water Vapor Ablation System. The acquisition builds on over 30 years of experience in women’s healthcare and complements CooperSurgical’s growing portfolio of medical products focused on clinic and practice-based women’s health.
Mara is an endometrial ablation treatment that uses water vapor to safely treat heavy menstrual bleeding, specifically designed for use in the doctor’s office. Mara is a two-minute, in-office treatment that ablates the lining of the uterus, the source of heavy menstrual bleeding in women who have not reached menopause. Heavy menstrual bleeding, also known as menorrhagia, is a common condition about one-third of women seek treatment for during their lifetimes1.
Clinical study data demonstrates that Mara safely and effectively reduces heavy menstrual bleeding and improves a woman’s quality of life. Mara treats patients with myomas, large cavities and also provides post-ablation cavity access.
“I’d like to thank Maria Sainz and her team, CEO of AEGEA, for her dedication to innovation in women’s health,” said Holly Sheffield, President of CooperSurgical. “The Mara Water Vapor Ablation System gives women a great option for a safe and convenient in-office procedure to help with what can often be a debilitating health issue.”
Mara Clinical Results
One year after treatment in an international, multi-center pivotal clinical trial that enrolled 155 women, 93% of women reported no to moderate bleeding2. Results also demonstrated the following:
- 99% of patients experienced improvement in quality of life3
- 91% of patients satisfied or very satisfied with procedure2,3
- 93% said they would recommend it to a friend2
For clinical information or a demo of Mara, please visit coopersurgical.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) receives US clearance of proposed acquisition of Alexion (ALXN)
- Castor Maritime Inc. (CTRM) Announces Vessel Acquisition
- RealPage's (RP) to be halted April 21 ahead of closing of merger, says Nasdaq
Create E-mail Alert Related CategoriesCorporate News, Mergers and Acquisitions
Related EntitiesDefinitive Agreement, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!